Evaluating CM336 for treating autoimmune bullous disease in adults
Official title: An Open-label, PhaseⅡ Study to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults With Moderate to Severe Autoimmune Bullous Disease
Run by Shandong First Medical University · NCT06900010 · Data updated 2026-11-12
This study is testing a new treatment called CM336 to see if it can help adults with moderate to severe autoimmune bullous disease feel better.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Shandong First Medical University Academic / other |
| Locations | 1 site (Jinan) |
| Status | Recruiting |
| Started | April 22, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2028 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT06900010 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of autoimmune bullous disease.
✕Probably not a fit
Patients with a history of significant diseases that may pose safety risks or those who have previously received BCMA therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to assess the efficacy and safety of CM336, a bispecific antibody targeting BCMA/CD3, in adults diagnosed with moderate to severe autoimmune bullous disease. Participants will receive injections of CM336 and will be monitored for their response to the treatment. The study includes both Phase 1 and Phase 2 evaluations to determine the optimal dosage and effectiveness of the intervention. Eligible participants must be at least 18 years old and provide informed consent to join the trial.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients suffering from autoimmune bullous disease.
How similar studies have gone: While this approach is novel in the context of autoimmune bullous disease, similar bispecific antibody therapies have shown promise in other conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Confirmed diagnosis of autoimmune bullous disease； * 2\. Age ≥18 years, regardless of gender； * 3\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements. Exclusion Criteria: * 1\. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation； * 2\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy； * 3\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336； * 4\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.
Where it's running
-
Dermatology Hospital of Shandong First Medical University
Jinan, China Recruiting
Study contacts
- Principal investigator: Furen Zhang — Dermatology Hospital of Shandong First Medical University
- Study coordinator: Furen Zhang
- Email: splcsy@126.com
- Phone: 15854179852
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SHR-1139 Injection for Ulcerative Pyoderma Gangrenosum in Adults
This study tests whether SHR-1139 injections can help adults with ulcerative pyoderma gangrenosum and how safe the treatment is.
-
Yangxinshi tablets for improving exercise capacity in chronic coronary syndrome patients
This study is testing if adding Yangxinshi tablets to standard treatment can help people with chronic coronary syndrome walk farther and improve their exercise ability.
-
Evaluating biomarkers for coronary heart disease prognosis
This study is trying to find out which blood and stool markers can help predict health outcomes for people with coronary heart disease over two years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.